A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer.
Breast Cancer Research and Treatment.
Times cited: 27
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2-overexpressing breast cancer: A phase I dose-escalation study.
Journal of Clinical Oncology.
Times cited: 279